Results 61 to 70 of about 19,854 (197)

Plasma PCSK9 preferentially reduces liver LDL receptors in mice*

Journal of Lipid Research, 2008
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that regulates the expression of LDL receptor (LDLR) protein. Gain-of-function mutations in PCSK9 cause hypercholesterolemia, and loss-of-function mutations result in lower ...
Aldo Grefhorst, Markey C. McNutt, Thomas A. Lagace, Jay D. Horton   +3 more
doaj   +1 more source

Targeting PCSK9 in Vascular Smooth Muscle Cells: An Effective Strategy to Suppress Ferroptosis and Attenuate Abdominal Aortic Aneurysm Progression

Cell Proliferation, EarlyView.
PCSK9 aggravates AAA by promoting ferroptosis in VSMCs. In the pathological AAA environment, PCSK9 upregulation triggers ferritinophagy‐dependent degradation of FTH1, leading to Fe2+ release, triggering lipid peroxidation and ferroptosis, exacerbating AAA.
Mengdie Xia, Man Li, Yanyu Chen, Jialin Chen, Yuting Cui, Xi‐Long Zheng, Jing Yang, Bingzhao Li, Xiaofeng Ma, Miao Liu, Gang Fan, Juan Peng, Xiaoyan Dai, Zhihan Tang   +13 more
wiley   +1 more source

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source

PCSK9 monoclonal antibodies: An overview

Heart Views, 2020
PCSK9 monoclonal antibodies are novel lipid-lowering therapy that have been extensively studied in patients with hypercholesterolemia either as monotherapy or as an add-on to other LLTs. PCSK9 monoclonal antibodies have significantly reduced the low-density lipoprotein cholesterol (LDL-C) plasma level resulting in a better LDL-C goal attainment.
Rasha Kaddoura, Bassant Orabi, Amar M Salam   +2 more
openaire   +3 more sources

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

Lipids in Health and Disease, 2008
Background Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein that is transcriptionally regulated by cholesterol status. It modulates levels of circulating low density lipoprotein cholesterol (LDLC) by negatively regulating ...
Mbikay Majambu, LaHaye Stephen A, Lahey Karen A, Chaplin Anna, Cousins Marion, Raymond Angela, Dewpura Thilina, Mayne Janice, Ooi Teik, Chrétien Michel   +9 more
doaj   +1 more source

The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities

Journal of Internal Medicine, EarlyView.
Abstract Type 2 diabetes (T2D) is a major global health concern strongly associated with atherosclerosis and subsequent macrovascular complications. These complications are the leading cause of death among T2D patients. Despite a decline in cardiovascular events over the last decade, individuals with T2D still have an approximately doubled risk ...
Dania Al‐Sharify, Jiangming Sun, Andreas Edsfeldt   +2 more
wiley   +1 more source

Sex‐specific metabolic responses to glucagon receptor agonism and modulation of the FGF21‐glucagon axis in female mice

The Journal of Physiology, EarlyView.
Abstract figure legend Therapies targeting the glucagon receptor are being explored for obesity treatment, yet most preclinical studies remain male biased. In this study, Merrild and Johansen et al. show that in diet‐induced obese wild‐type mice a long‐acting glucagon analogue (LA‐Gcg) elicits sexually dimorphic effects on weight loss, food intake ...
Christoffer Merrild, Valdemar Brimnes Ingemann Johansen, Christoffer Clemmensen, Pablo Ranea‐Robles   +3 more
wiley   +1 more source

PCSK9-Inhibitoren

Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, 2017
Hypercholesterolemias are known risk factors for cardiovascular diseases. Although statins have reduced the cardiovascular morbidity and mortality and further therapeutic measures are available, treatment goals are often not achieved. In cases of very high levels of low-density lipoprotein (LDL) cholesterol or of intolerability, the established ...
Lyko, Christina, Blum, Manuel R, Aubert, Carole E, Gencer, Baris, Rodondi, Nicolas, Collet, Tinh-Hai   +5 more
openaire   +3 more sources

FURIN induces vascular endothelial cell death and efferocytosis through enzymatic cleavage of thrombospondin‐1

The Journal of Physiology, EarlyView.
Abstract figure legend FURIN induces vascular endothelial cell (VEC) death and efferocytosis through enzymatic cleavage of thrombospondin‐1 (THBS1). FURIN interacts with THBS1 to induce VEC apoptosis and efferocytosis, resulting in increased endothelial permeability.
Runji Chen, Daifei Shen, Amandine Mahieux, Dedrick Song, Shiwan Wu, Xiaoxin Huang, Xu Yang, Kunwei Chen, David G. McVey, Elisa A. Liehn, Roshni R. Singaraja, Shu Ye   +11 more
wiley   +1 more source

Genetic screening and response to drug therapy in familial hypercholesterolemia

Frontiers in Molecular Biosciences
ObjectivesFamilial hypercholesterolemia (FH) is an autosomal genetic disorder, which is significantly underdiagnosed. Here, we aimed to identify the genetic causes of a FH family and clarify the clinical diagnosis of the patient and then provide ...
Yuzhi Lu, Yuzhi Lu, Yuzhi Lu, Qianwen Chen, Qianwen Chen, Qianwen Chen, Qianwen Chen, Wenjuan Zhang, Wenjuan Zhang, Wenjuan Zhang, Wenjuan Zhang, Jiangtao Dong, Jiangtao Dong, Jiangtao Dong, Jiangtao Dong, Lingfeng Zha, Lingfeng Zha, Lingfeng Zha   +17 more
doaj   +1 more source